Vertex Pharmaceuticals
Preço: 444.93Empresa e modelo de negócios
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases, primarily cystic fibrosis. Its core products include Kalydeco, Orkambi, Symdeko, and Trikafta, which target the underlying causes of cystic fibrosis. The company generates revenue mainly from product sales and has a strong pipeline of potential therapies in various stages of development.
Perfil de investimento
The investment profile of Vertex Pharmaceuticals is more aligned with growth investors, given its focus on innovation and potential for future revenue expansion through new therapies. The absence of dividends suggests a reinvestment strategy aimed at long-term growth. The stock may appeal to those with a medium to long-term investment horizon, while its moderate volatility indicates a need for a basic level of market experience.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 17.01 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -7.4% ↓
- Surpresa de EPS
- 5.4% melhor que o esperado
- Volatilidade 20d
- 1.6% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-11 05:28 | Manter | Vender | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-16 02:35 | Comprar | Manter | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-14 02:35 | Vender | Comprar | Mixed performance; watch for recovery signs. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-27 05:02 | Truist Financial | Atualizar | — → 542 | 435.93 |
| 2026-05-06 09:48 | Barclays | Preço-alvo elevado | 607 → 615 | 424.36 |
| 2026-05-05 12:24 | Morgan Stanley | Preço-alvo elevado | 612 → 616 | 417.72 |
Nada ainda